Material Agreements - Additional Information (Detail)				1 Months Ended						12 Months Ended
	Jun. 06, 2022 $ / shares shares	Nov. 03, 2021 shares	Oct. 18, 2021 $ / shares shares	Dec. 31, 2022 USD ($)	May 31, 2021 USD ($)	Mar. 31, 2021 USD ($) tranche shares	Dec. 31, 2020 USD ($)	Aug. 31, 2020 USD ($) shares	Oct. 31, 2019 USD ($) tranche shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 16, 2022 USD ($)	Oct. 12, 2021 shares	Nov. 30, 2020 USD ($)
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares						125,000
Number of tranches | tranche						3			3
Warrants issued during period (in shares) | shares						3
Payment of milestone amount										$ 1,650,000	$ 0
Tarsus Warrants
License And Other Related Agreements [Line Items]
Number of securities called by each warrant or right (in shares) | shares			156,746
Navire | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement								$ 8,000,000
Payment towards development amount in connection with license agreement				$ 0						0	8,500,000
Navire | Maximum | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales								15.00%
Navire | Minimum | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales								5.00%
Navire | Specified Development Regulatory Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount								$ 24,500,000
Navire | Sales Based Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone								357,600,000
QED | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement									$ 10,000,000
QED | Specified Development Regulatory Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount									7,000,000
QED | Sales Based Milestone | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone									87,500,000
QED | Lian Oncology | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants and rights outstanding value									$ 1,000,000
Class of warrants or rights expiry period									10 years
QED | Lian Oncology | Tranche One | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity									10.00%
QED | Lian Oncology | Tranche Two | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity									10.00%
QED | Lian Oncology | Tranche Three | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity									10.00%
QED | Lian Oncology | Warrants To Purchase Common Stock | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares			347,569						100,000
Class of warrants or rights exercise price (in dollars per share) | $ / shares			$ 0.000017100448
Myokardia
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement								40,000,000
Myokardia | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount								60,000,000
Payment of milestone amount										5,000,000.0
Myokardia | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone								87,500,000
Myokardia | Non Refundable Financing Milestone Payment
License And Other Related Agreements [Line Items]
Milestone payment payable								35,000,000
Imputed interest on milestone payment								$ 2,300,000
Myokardia | Non Refundable Financing Milestone Payment | Amended Licensing Agreement
License And Other Related Agreements [Line Items]
Payment of milestone amount							$ 35,000,000
Myokardia | Warrants To Purchase Common Stock
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares								170,000					170,000
Warrants and rights outstanding value								$ 33,800,000
Warrants or rights issuable as a percentage of fully diluted equity								17.00%
Pfizer
License And Other Related Agreements [Line Items]
Commitment to contribute capital														$ 70,000,000
Upfront payment receivable												$ 20,000,000.0		$ 20,000,000
Milestone continent consideration				135,000,000.0
Reimbursement amount				7,000,000.0
Gain contingency				$ 13,000,000.0
Reviral
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						$ 14,000,000
Payment of milestone amount										0
Reviral | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						45,000,000
Reviral | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						60,000,000
Reviral | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						105,000,000
Tarsus Pharmaceuticals
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement						15,000,000
Payment of milestone amount										25,000,000.0	$ 30,000,000
Tarsus Pharmaceuticals | Milestone Stage Two
License And Other Related Agreements [Line Items]
Milestone payment payable						10,000,000
Tarsus Pharmaceuticals | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						75,000,000
Tarsus Pharmaceuticals | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone						100,000,000
Tarsus Pharmaceuticals | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount						$ 175,000,000
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock
License And Other Related Agreements [Line Items]
Class of warrants or rights number of securities covered by the warrants or rights (in shares) | shares						125,000
Warrants and rights outstanding value						$ 9,400,000
Class of warrants or rights expiry period						10 years
Class of warrants or rights exercise price (in dollars per share) | $ / shares	$ 0.000017100448		$ 0.000017100448
Warrants issued during period (in shares) | shares			2			3
Issuance of ordinary shares upon initial public offering, net of issuance costs (in shares) | shares	78,373	78,373
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche One
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity						12.50%
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Two
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity						12.50%
Tarsus Pharmaceuticals | Warrants To Purchase Common Stock | Tranche Three
License And Other Related Agreements [Line Items]
Warrants or rights issuable as a percentage of fully diluted equity						12.50%
Landos
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement					$ 18,000,000
Payment of milestone amount										0
Landos | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount					95,000,000
Landos | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone					105,000,000
Landos | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount					200,000,000
Nanobiotix
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement					$ 20,000,000
Payment of milestone amount										0
Nanobiotix | Maximum
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales					13.00%
Nanobiotix | Minimum
License And Other Related Agreements [Line Items]
Tiered royalty as a percentage of net sales					10.00%
Nanobiotix | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount					$ 65,000,000
Nanobiotix | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone					155,000,000
Nanobiotix | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount					220,000,000
Lyra
License And Other Related Agreements [Line Items]
Payment towards upfront amount in connection with license agreement					12,000,000
Payment of milestone amount										$ 5,000,000.0
Lyra | Specified Development Regulatory Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount					40,000,000
Lyra | Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, net sales milestone					95,000,000
Lyra | Specified Development Regulatory And Sales Based Milestone
License And Other Related Agreements [Line Items]
Asset acquisition, milestone, amount					$ 135,000,000